Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame.The outperformance...
Biopharma major Incyte is expected to announce its fourth-quarter results later this month and analysts expect a significant double-digit growth in earnings.
Incyte has outperformed the Dow recently, and analysts remain moderately optimistic about the stock’s prospects.
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally. Royalty Pharma (NASDAQ: RPRX), W.P. Carey (NYSE: WPC) , and Omega Healthcare Investors...
Vijay K Iyengar, the EVP of $INCY ($INCY), sold 5,683 shares of the company on 11-29-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 15.6% of their shares....
Despite Incyte Corporation’s underperformance relative to the broader S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.
December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.14% this morning as investors shifted their focus to a highly anticipated earnings report from AI darling Nvidia.
The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.28%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.71%. Stocks on Tuesday...
Incyte suspended testing of a drug candidate acquired through its April acquisition of Escient Pharmaceuticals and abandoned development of another, undermining its diversification strategy.
The S&P 500 Index ($SPX ) (SPY ) today is down -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.11%. Stocks are mixed today, with...